Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH) (MESH)
Outcomes of Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma; Middle Meningeal Artery Embolization for Chronic Subdural Hematoma (MESH)
Sponsor: Cornell University
Listed as NCT06181994, this observational or N/A phase trial focuses on Chronic Subdural Hematoma and remains actively recruiting participants. Sponsored by Cornell University, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Recruiting
-
Sep 2025 — Feb 2026 [monthly]
Recruiting
-
Jan 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 1 earlier version
-
Jan 2024 — Jul 2024 [monthly]
Recruiting
First recorded
Dec 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cornell University
- Geisinger Clinic
- Heidelberg University
- Henri Mondor University Hospital
- Lehigh Valley Hospital
- Mayo Clinic
- Medical University of South Carolina
- Montefiore Medical Center
- New York University
- Oregon Health and Science University
- Ospedale Policlinico San Martino
- Ospedale San Raffaele
- Sisters of Mercy University Hospital
- Sutter Health
- Thomas Jefferson University
- Unity Health Toronto
- University Health Network, Toronto
- University Hospital, Bordeaux
- University of Alabama at Birmingham
- University of Iowa
- University of South Florida
- University of Washington
- Westchester Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .